Editing AUA: Overactive Bladder (2019) (section)

===== Efficacy =====
*Significant symptom reductions for voids per day and incontinence episodes per day
*Improvements in UUI, urgency episodes, and QOL measures also occur but were not as consistently statistically significant. 
*Among studies with an active control group administered tolterodine ER 4 mg/daily, mirabegron generally performed similarly to tolterodine. Higher doses of mirabegron did not produce greater effects.